Synapse Open Synapse
Biology

Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

BioPharma Dive · · 2 min read

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.

Latest from BioPharma Dive